A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
| Autor: | William C. Cushman, Stuart Kupfer, Eric E. Lloyd, Andrew V. Roberts, Domenic A. Sica, George L. Bakris, Michael A. Weber, William B. White |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty hypertension Ambulatory blood pressure Physiology Systolic hypertension Urology Tetrazoles Blood Pressure 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Hydrochlorothiazide Double-Blind Method Internal Medicine medicine Humans 030212 general & internal medicine Azilsartan Medoxomil Diuretics antihypertensive therapy Antihypertensive Agents Aged Oxadiazoles business.industry Imidazoles Chlorthalidone azilsartan medoxomil Middle Aged medicine.disease angiotensin II receptor blocker fixed-dose combination Drug Combinations thiazide-like diuretic Benzimidazoles Female CTD Cardiology and Cardiovascular Medicine business Olmesartan ORIGINAL PAPERS: Therapeutic aspects Kidney disease medicine.drug |
| Zdroj: | Journal of Hypertension |
| ISSN: | 0263-6352 |
| DOI: | 10.1097/hjh.0000000000001647 |
| Popis: | Background: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). Objective/methods: We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160–190 mmHg and DBP 119 mmHg or less. Titration to higher doses occurred at week 4 if BP was at least 140/90 mmHg (≥130/80 mmHg if diabetes or chronic kidney disease). The primary endpoint was change from baseline in clinic SBP; 24-h ambulatory BP monitoring was also measured. Results: Greater reductions in clinic SBP from a baseline of 165 mmHg were observed (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|